| Attribute |
Value |
| 52 Week Change |
-0.3466667 |
| Address1 |
12,407 N. Mopac Expy. |
| Address2 |
Suite 250 #390 |
| All Time High |
309.6 |
| All Time Low |
0.864 |
| Ask |
0.9893 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
425,810 |
| Average Daily Volume3 Month |
802,029 |
| Average Volume |
802,029 |
| Average Volume10Days |
425,810 |
| Beta |
1.348 |
| Bid |
1.01 |
| Bid Size |
3 |
| Book Value |
-1.192 |
| City |
Austin |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.9075 |
| Current Ratio |
0.4 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
0.999 |
| Day Low |
0.8706 |
| Debt To Equity |
42.473 |
| Display Name |
Rein Therapeutics |
| Earnings Timestamp End |
1,755,547,200 |
| Earnings Timestamp Start |
1,755,028,800 |
| Ebitda |
-21,566,500 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-5.708 |
| Enterprise Value |
123,109,672 |
| Eps Trailing Twelve Months |
-1.9 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.03094 |
| Fifty Day Average Change |
-0.12344003 |
| Fifty Day Average Change Percent |
-0.119735405 |
| Fifty Two Week Change Percent |
-34.666668 |
| Fifty Two Week High |
2.18 |
| Fifty Two Week High Change |
-1.2725 |
| Fifty Two Week High Change Percent |
-0.5837156 |
| Fifty Two Week Low |
0.864 |
| Fifty Two Week Low Change |
0.043500006 |
| Fifty Two Week Low Change Percent |
0.050347228 |
| Fifty Two Week Range |
0.864 - 2.18 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,498,743,000,000 |
| Float Shares |
71,502,932 |
| Free Cashflow |
-8,098,000 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
10 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.055040002 |
| Held Percent Institutions |
0.24615999 |
| Implied Shares Outstanding |
85,539,032 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,668,124,800 |
| Last Split Factor |
1:20 |
| Long Business Summary |
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas. |
| Long Name |
Rein Therapeutics Inc. |
| Market |
us_market |
| Market Cap |
77,626,672 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_21766697 |
| Most Recent Quarter |
1,774,915,200 |
| Name Change Date |
2,026-07-13 |
| Net Income To Common |
-50,208,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
77,626,671 |
| Number Of Analyst Opinions |
1 |
| Open |
0.96 |
| Operating Cashflow |
-16,610,000 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
737 802 1989 |
| Prev Name |
Aileron Therapeutics, Inc. |
| Previous Close |
0.98 |
| Price Hint |
4 |
| Price To Book |
-0.7613255 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.326 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.0725 |
| Regular Market Change Percent |
-7.39796 |
| Regular Market Day High |
0.999 |
| Regular Market Day Low |
0.8706 |
| Regular Market Day Range |
0.8706 - 0.999 |
| Regular Market Open |
0.96 |
| Regular Market Previous Close |
0.98 |
| Regular Market Price |
0.9075 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
641,369 |
| Return On Assets |
-0.32104 |
| Return On Equity |
-1.63358 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
85,539,032 |
| Shares Percent Shares Out |
0.0105 |
| Shares Short |
898,096 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
387,486 |
| Short Name |
Rein Therapeutics, Inc. |
| Short Percent Of Float |
0.0105 |
| Short Ratio |
1.38 |
| Source Interval |
15 |
| State |
TX |
| Symbol |
RNTX |
| Target High Price |
8.0 |
| Target Low Price |
8.0 |
| Target Mean Price |
8.0 |
| Target Median Price |
8.0 |
| Total Cash |
4,445,000 |
| Total Cash Per Share |
0.052 |
| Total Debt |
4,923,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-1.9 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.26406 |
| Two Hundred Day Average Change |
-0.35656 |
| Two Hundred Day Average Change Percent |
-0.2820752 |
| Type Disp |
Equity |
| Volume |
641,369 |
| Website |
https://www.reintx.com |
| Zip |
78,758 |